Literature DB >> 24906792

Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides?

Alessandro Conrado de Oliveira Silveira1, Gustavo Enck Sambrano2, Thiago Galvão da Silva Paim2, Juliana Caierão2, Caio Mauricio Mendes de Cordova3, Pedro Alves d'Azevedo2.   

Abstract

The characterization of heteroresistant vancomycin-intermediate Staphylococcus aureus strains (hVISA) is even more challenging, as no routine standardized laboratory methods are available. A total of 124 S. aureus isolates recovered from inpatients attended in hospitals of Santa Catarina State, Southern Brazil, were evaluated. The MIC of vancomycin, teicoplanin, and daptomycin was determined by Etest and prediffusion tests using NeoSensitabs® tablets. All isolates were susceptible to vancomycin (MICs: 0.5-3 μg/mL) by Etest. However, according to prediffusion test, 17 isolates presented reduced susceptibility to vancomycin, and of these, 12 were confirmed as hVISA using populational analysis. Considering daptomycin, prediffusion results were in agreement with susceptibility data (MICs), as all isolates were susceptible. Considering that characterizing hVISA is challenging and that MIC determination is not adequate to characterize this phenotype, prediffusion test was a viable alternative to screening hVISA and reduced susceptibility to vancomycin. It was simple and low cost, with accuracy comparable to other well-established methods.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heteroresistant vancomycin intermediate; MRSA; Staphylococcus aureus; Vancomycin resistance

Mesh:

Substances:

Year:  2014        PMID: 24906792     DOI: 10.1016/j.diagmicrobio.2014.04.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

2.  Broad-range lytic bacteriophages that kill Staphylococcus aureus local field strains.

Authors:  Virginia Abatángelo; Natalia Peressutti Bacci; Carina A Boncompain; Ariel F Amadio; Soledad Carrasco; Cristian A Suárez; Héctor R Morbidoni
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

3.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 4.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

5.  Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.

Authors:  Thaina Miranda da Costa; Priscylla Guimarães Migueres Morgado; Fernanda Sampaio Cavalcante; Andreia Paredes Damasco; Simone Aranha Nouér; Kátia Regina Netto Dos Santos
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.